Table 2 Clinical and pathological characteristics according to progression in patients with recurrence
Characteristics | No (n = 46) (%) | Yes (n = 27) (%) | p value |
|---|---|---|---|
Age (year) at diagnosis | 0.022 | ||
< 40 | 14 (30.4) | 2 (7.4) | |
≥40 | 32 (69.6) | 25 (92.6) | |
Breast operation | 0.528 | ||
Breast conserving surgery | 29 (63.0) | 15 (55.6) | |
Mastectomy | 17 (37.0) | 12 (44.4) | |
Axilla operation | 0.014 | ||
No | 1 (2.2) | 0 | |
SLNB | 20 (43.5) | 4 (14.8) | |
ALND | 25 (54.3) | 23 (85.2) | |
pT | 0.007 | ||
1 | 32 (69.6) | 10 (37.0) | |
2 | 14 (30.4) | 17 (63.0) | |
pN | 0.206 | ||
0 | 35 (76.1) | 17 (63.0) | |
1 | 8 (17.4) | 7 (25.9) | |
2 | 3 (6.5) | 1 (3.7) | |
3 | 0 | 2 (7.4) | |
Pathologic stage | 0.007 | ||
I | 43 (93.5) | 18 (66.7) | |
II | 3 (6.5) | 7 (25.9) | |
III | 0 | 2 (7.4) | |
ER status | 1.000 | ||
Negative | 1 (2.2) | 1 (3.7) | |
Positive | 45 (97.8) | 26 (96.3) | |
PR status | 0.384 | ||
Negative | 8 (17.4) | 7 (25.9) | |
Positive | 38 (82.6) | 20 (74.1) | |
HG | 0.095 | ||
1 | 15 (32.6) | 3 (11.1) | |
2 | 22 (47.8) | 15 (55.6) | |
3 | 9 (19.6) | 9 (33.3) | |
Ki-67 | 0.319 | ||
≤15% | 26 (56.5) | 12 (44.4) | |
> 15 | 20 (43.5) | 15 (55.6) | |
LVI | 0.012 | ||
No | 33 (71.7) | 11 (40.7) | |
Yes | 12 (26.1) | 16 (59.3) | |
Unknown | 1 (2.2) | 0 | |
Adjuvant chemotherapy | 0.646 | ||
No | 23 (50.0) | 12 (44.4) | |
Yes | 23 (50.0) | 15 (55.6) | |
Adjuvant radiotherapy | 0.412 | ||
No | 16 (34.8) | 12 (44.4) | |
Yes | 30 (65.2) | 15 (55.6) | |
Adjuvant endocrine therapy | 1.000 | ||
No | 2 (4.3) | 1 (3.7) | |
Yes | 44 (95.7) | 26 (96.3) | |
Site of first recurrence | 0.101 | ||
Breast | 30 (65.2) | 10 (37.0) | |
Axilla | 7 (15.2) | 7 (25.9) | |
Chest wall or skin | 7 (15.2) | 7 (25.9) | |
Breast + axilla or axilla + chest wall | 2 (4.3) | 3 (11.1) | |
Number of recurrence | 0.352 | ||
One | 44 (95.7) | 24 (88.9) | |
Two or more | 2 (4.3) | 3 (11.1) | |
Post-recurrence chemotherapy | 0.138 | ||
No | 27 (58.7) | 11 (40.7) | |
Yes | 19 (41.3) | 16 (59.3) | |
Post-recurrence radiotherapy | 0.869 | ||
No | 35 (76.1) | 21 (77.8) | |
Yes | 11 (23.9) | 6 (22.2) | |
Post-recurrence endocrine therapy | <0.001 | ||
No | 9 (19.6) | 18 (66.7) | |
Yes | 37 (80.4) | 9 (33.3) | |
Selective estrogen receptor modulators | 15 (40.5) | 7 (77.8) | |
Aromatase inhibitors | 22 (59.5) | 2 (22.2) | |
Death | <0.001 | ||
No | 46 (100) | 13 (48.1) | |
Yes | 0 | 14 (51.9) | |